Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals
News Mar 26, 2014
Courtagen Life Sciences has announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders.
Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
“The genetic profiling of patients is expected to elucidate important information beneficial to Raptor’s clinical trial for RP103,” said Brian McKernan, CEO of Courtagen.
McKernan continued, “We are pleased to work with Raptor Pharmaceuticals and believe that Courtagen’s mtSEEK® and nucSEEK® Next Generation Sequencing tests offer the most comprehensive mitochondrial analysis for such clinical trial work.”
Ancient Fish Genes May Hold Key to Spinal Cord RepairNews
A study has found that genes controlling spinal cord repair in the lamprey fish are also active in mammals, which could provide a blueprint for treatment.READ MORE
Prostate Tumor Progression Dictated by Cancer’s Gene-determined “Immune Landscape”News
The field of immunotherapy is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.READ MORE